Speciality: Dermatology
Description:
A warm welcome to all the medical professionals in this interesting session on Managing Psoriatic Diseases : Where do we stand and unmet need
Managing psoriatic diseases has advanced significantly over the years, with the development of targeted therapies, particularly biologics, revolutionizing treatment. These therapies, which include TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors, have dramatically improved outcomes for patients with moderate to severe psoriasis and psoriatic arthritis. These treatments effectively reduce inflammation, clear skin lesions, and prevent joint damage, offering patients a higher quality of life. However, despite these advancements, several unmet needs remain in the management of psoriatic diseases.
One of the key challenges is that not all patients respond to current therapies, and some may experience diminished effectiveness over time. Additionally, long-term safety data for newer treatments is still evolving, and some patients may develop side effects that limit their use. There is also a need for more personalized treatment strategies, as psoriatic diseases vary widely in severity, symptoms, and response to treatment. Another significant unmet need is addressing the comorbid conditions associated with psoriatic diseases, such as cardiovascular disease, metabolic syndrome, and mental health disorders, which require comprehensive, coordinated care.
Therefore, get an overall knowledge of managing psoriatic diseases : Where do we stand and unmet need
See More Webinars @ Hidoc Webinars
1.
A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.
2.
Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment
3.
Racial differences seen in epigenetic age acceleration in childhood cancer survivors
4.
ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer
5.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
1.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
2.
The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025
3.
Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning
4.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
5.
How to Prevent Tumor Lysis Syndrome in Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
5.
Navigating the Complexities of Ph Negative ALL - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation